Interestingly, an immunotherapeutic approach that targets CD22, epratuzumab, has proved efficacious in the treatment of non-Hodgkin lymphoma, and in the autoimmune diseases, systemic lupus erythematosus and primary Sjögren's syndrome [30]. The gene discussed is CD22; the disease is Sjogren syndrome.